Columbia Seligman Premium Technology Growth Fund (STK)
Stock analysis · NYSE · Financial Services · Asset Management
Columbia Seligman Premium Technology Growth Fund (STK) is a publicly traded company in the Financial Services sector. Latest price: $52.18. Market cap $921.77M. Trailing PE 1.73. Dividend yield 6.09%. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.
Get full analysis → Short-Term Analysis →You have viewed 4 SEO analysis pages
Unlock saved watchlists, personalized setups, and referral credits with a free Stocks360 account.
Continue with free signup1-Year Price
Proprietary Signals
About Columbia Seligman Premium Technology Growth Fund
The Columbia Seligman Premium Technology Growth Fund is a closed-end equity mutual fund, overseen by Columbia Management Investment Advisers, LLC. This U.S.-domiciled fund, established on November 30, 2009, (and formerly known as the Seligman Premium Technology Growth Fund, Inc.) allocates capital to public equity markets. Its core investment strategy involves primarily targeting growth companies within the technology sector. The fund's portfolio is built through fundamental analysis, identifying businesses that exhibit strong growth prospects, attractive valuations, and the capacity to generate consistent investment returns over time. Its performance is benchmarked against the S&P North American Technology Sector Index.
Valuation
| P/E (TTM) | 1.73× |
|---|---|
| P/S (TTM) | 3.25× |
| P/B | 0.91× |
| PEG | 0.00× |
| P/FCF (TTM) | 0.00× |
| EV / EBITDA | 1.73× |
| EV / Sales | 3.25× |
| Earnings Yield | 57.65% |
| Free Cash Flow Yield | 0.00% |
| Dividend Yield | 6.09% |
Fundamentals
| Enterprise Value | $921.77M |
|---|---|
| Revenue (TTM) | $283.60M |
| Net Income (TTM) | $531.42M |
| Free Cash Flow (TTM) | $0.00 |
| Net Debt | $0.00 |
| Working Capital | -$4.48M |
| Gross Margin | 97.31% |
| Operating Margin | 187.37% |
| Net Margin | 187.37% |
| Return on Equity | 63.02% |
| Return on Invested Capital | 51.99% |
Peers
Recent News
- STK Vs. TDVI: The Unicorn CEF And Its Closest ETF Equivalent
- Stoke Therapeutics Presents Data Supporting the Disease-Modifying Potential of STK-002 in Autosomal Dominant Optic Atrophy (ADOA) at the Am…
- Columbia Seligman Premium Technology Growth Fund Announces a Fourth Quarter Distribution: 9.25% Annual Rate for IPO Investors
- Stoke Therapeutics Announces Presentations of STK-002, an Investigational Medicine for the Treatment of Autosomal Dominant Optic Atrophy (A…
- How To Potentially Retire In Your 40s
Related
Browse more tickers: sitemap